Analysts are on the Bearish side about Flex Pharma, Inc. (NASDAQ:FLKS) this week.

June 16, 2018 - By Marry Poplack

Flex Pharma, Inc. (NASDAQ:FLKS) Logo

Flex Pharma, Inc. (NASDAQ:FLKS) Ratings Coverage

Among 3 analysts covering Flex Pharma (NASDAQ:FLKS), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Flex Pharma had 5 analyst reports since January 25, 2018 according to SRatingsIntel. The stock of Flex Pharma, Inc. (NASDAQ:FLKS) earned “Buy” rating by Jefferies on Tuesday, February 13. The stock of Flex Pharma, Inc. (NASDAQ:FLKS) earned “Buy” rating by H.C. Wainwright on Thursday, March 8. Jefferies maintained Flex Pharma, Inc. (NASDAQ:FLKS) rating on Friday, April 6. Jefferies has “Buy” rating and $700 target. The stock of Flex Pharma, Inc. (NASDAQ:FLKS) earned “Neutral” rating by Ladenburg Thalmann on Wednesday, June 13. Below is a list of Flex Pharma, Inc. (NASDAQ:FLKS) latest ratings and price target changes.

13/06/2018 Broker: Ladenburg Thalmann Old Rating: Buy New Rating: Neutral Old Target: $12 Downgrade
06/04/2018 Broker: Jefferies Rating: Buy New Target: $7.0000 Maintain
08/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $40.0 Maintain
13/02/2018 Broker: Jefferies Rating: Buy New Target: $6.0 Maintain
25/01/2018 Broker: Ladenburg Thalmann Rating: Buy New Target: $12 Initiates Coverage On

The stock decreased 3.70% or $0.05 during the last trading session, reaching $1.3. About 1.45M shares traded or 373.27% up from the average. Flex Pharma, Inc. (NASDAQ:FLKS) has risen 16.07% since June 16, 2017 and is uptrending. It has outperformed by 3.50% the S&P500.

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company has market cap of $23.42 million. The firm operates through two divisions, Consumer Operations and Drug Development. It currently has negative earnings. The Company’s lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis.

More notable recent Flex Pharma, Inc. (NASDAQ:FLKS) news were published by: Benzinga.com which released: “Benzinga’s Biggest Movers For The Week Of June 11, 2018” on June 15, 2018, also Streetinsider.com with their article: “Pre-Open Movers 06/13: (ENPH) (CANF) (BITA) Higher; (FLKS) (VTVT) (HRB) Lower (more…)” published on June 13, 2018, Streetinsider.com published: “Flex Pharma (FLKS) Says it is Ending Phase 2 Clinical Trials of FLX-787 in ALS and CMT Due to Oral Tolerability …” on June 13, 2018. More interesting news about Flex Pharma, Inc. (NASDAQ:FLKS) were released by: Nasdaq.com and their article: “Mid-Day Market Update: Pivotal Software Gains Following Q1 Results; Flex Pharma Shares Slide” published on June 13, 2018 as well as Benzinga.com‘s news article titled: “Flex Pharma Shares Plunge After Biotech Ends 2 Clinical Trials, Announces 60% Workforce Cut” with publication date: June 13, 2018.

Flex Pharma, Inc. (NASDAQ:FLKS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: